Form 4: West Pharmaceutical Services Executive Reports Stock Transactions
SEC Form 4 Filing
Cindy Reiss-Clark, Chief Commercial Officer of West Pharmaceutical Services, reports the acquisition and disposal of company stock and stock options.
Summary
- On February 18, 2025, Cindy Reiss-Clark, Chief Commercial Officer of West Pharmaceutical Services, filed a Form 4.
- The filing reports the acquisition of 246.162 shares of Common Stock at a price of $211.
- The filing also reports the disposal of 83.179 shares of Common Stock at a price of $211.
- Following these transactions, Reiss-Clark beneficially owns 5,047.329 shares of Common Stock.
- Reiss-Clark also acquired 1,162 stock options with an exercise price of $211, exercisable beginning February 18, 2026, and expiring on February 18, 2035.
- Additionally, 503 Restricted Stock Units (RSUs) were acquired, vesting in four equal installments beginning on February 18, 2026.
- A Limited Power of Attorney was executed on May 14, 2024, granting Luis Cantarero, Louis Lalli, Ryan Metz, and Caitlin Hippeli the authority to execute Section 16(a) filings on behalf of Cindy Reiss-Clark.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with securities regulations.
Comparison to Industry Standards
- Insider trading activity is closely monitored across the pharmaceutical industry.
- Companies like Pfizer, Johnson & Johnson, and Merck also have executives who regularly file Form 4s to report their stock transactions.
- The volume and nature of these transactions are often compared to industry benchmarks to assess insider sentiment and potential future performance.
Stakeholder Impact
- The reported transactions may influence investor perception of the company's stock.
- Transparency in insider trading activity is important for maintaining shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-05-14 | Date of execution for the Limited Power of Attorney. |
| 2025-02-18 | Date of the reported stock transactions (acquisition and disposal). |
| 2026-02-18 | First vesting date for the stock options and RSUs. |
| 2035-02-18 | Expiration date for the stock options. |
Keywords
Form 4, stock options, restricted stock units, beneficial ownership, West Pharmaceutical Services, insider trading, securities, transactions, Reiss-Clark, WST
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.